Goldman Sachs Initiates Coverage On Cytokinetics with Buy Rating, Announces Price Target of $50
Portfolio Pulse from Benzinga Newsdesk
Goldman Sachs analyst Paul Choi has initiated coverage on Cytokinetics (NASDAQ:CYTK) with a Buy rating and a price target of $50.

November 09, 2023 | 12:31 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Goldman Sachs has initiated coverage on Cytokinetics with a Buy rating and a price target of $50.
The initiation of coverage by Goldman Sachs, a major investment bank, with a Buy rating indicates a positive outlook for Cytokinetics. The price target of $50 suggests significant upside potential from the current price. This could lead to increased investor interest and potentially a higher stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100